The group of Verma et al. for instance reported on the antineoplastic activity of an AKR1C3 inhibitor called KV-37, which reduced prostate tumor cell growth in vitro and in vivo associated with a reduction of PSA expression and reduced AR transactivation [22]. This evidence concerns the gene AR and prostate neoplasm.